AstraZeneca reports that AstraZeneca and Sanofi s Beyfortus has been approved in Japan for the prophylaxis of lower respiratory tract disease caused by respiratory syncytial virus in all newborns,.
Sanofi (SNY) and AstraZeneca (AZN) announce Beyfortus approved in Japan for the prevention of RSV disease in infants streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
First and only AKT inhibitor approved in Japan for breast cancer patients with specific biomarker alterations Approval based on CAPItello-291 results which showed.
Japan approves AstraZeneca & Sanofi's Beyfortus for respiratory syncytial virus in neonates, infants, & children. Also, Truqap receives approval for unresectable or recurrent breast cancer. AstraZeneca challenges Arkansas law extending drug discounts to for-profit pharmacy chains, citing federal regulations."